A recent study from the Mammalian Genetics Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom; and School of Medicine, King’s College London, London, United Kingdom shows that “Loss of Fbw7 Reprograms Adult Pancreatic Ductal Cells into α, δ, and β Cells.” This study was published in the 7 August issue of 2014 Cell Stem Cell (Number1 journal in Regenerative Medicine with an I.F of ~25) by Prof Axel Behrens, Rocio Sancho, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Anti-MiRNA-based Regenerative therapy for DM: MiRNA-22 inhibits reprogramming of adult pancreatic ductal cells into α, δ, and β cells via down regulation of Ngn3. This study suggests that MiRNA-22, by increasing the expression of Ngn3 in adult pancreatic ductal cells, it may reprogram adult pancreatic ductal cells into β cells. Thereby, it may induce the expression of Ngn3, increase insulin secretion and inhibit insulin resistance. Together, this study suggests that pharmacological formulations encompassing “MiRNA-22 inhibitors” may be used to regenerate β cells in DM patients.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Anti-MiRNA-based Regenerative therapy for DM: MiRNA-22 inhibits reprogramming of adult pancreatic ductal cells into α, δ, and β cells via down regulation of Ngn3, 10/October/2014, 6.56 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation